Post

New research · Ophthalmology
Ocular immunology and inflammation · 13h
StudyOcular immunology and inflammation · 2026

Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series.

Víctor Llorenç, Elisabetta Miserocchi, Cristina Fonseca, Uwe Pleyer
Read paper
OphthalmologyStudy

Fluocinolone acetonide implant associated with complete inflammation resolution in 92.9% of uveitis eyes

Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series.

Víctor Llorenç … Uwe Pleyer
Ocular immunology and inflammation · 2026
Purpose

To evaluate the effectiveness and safety of the 0.19 mg fluocinolone acetonide (fluocinolone acetonide) intravitreal implant for the management of immune checkpoint inhibitor (immune checkpoint inhibitor)-associated uveitis.

Methods

Multicenter retrospective case-series including patients who developed uveitis during immune checkpoint inhibitor therapy and were treated with a 0.19 mg fluocinolone acetonide implant.

n = 9 patients
Results
92.9%
vision-threatening eye inflammation went away completely in nearly all treated eyes
n = 9 patients
More results

Median time from immune checkpoint inhibitor initiation to uveitis onset was 5.0 months (interquartile range [IQR]: 2.0-6.0).

Best-reported visual acuity improved significantly from uveitis onset (0.79 ± 0.17 logMAR) to last follow-up (0.19 ± 0.04 logMAR; p = 0.0008).

More results

Anterior chamber cell, flare, and vitreous haze resolved in all eyes ( p < 0.001 for all comparisons).

IOP remained stable, with one transient elevation successfully controlled with topical therapy.

“
Conclusion · 1 of 2

The 0.19 mg fluocinolone acetonide intravitreal implant provided sustained control of inflammation, significant visual improvement, and reduced treatment burden in patients with immune checkpoint inhibitor-associated uveitis.

Conclusion · 2 of 2

This local therapeutic approach may facilitate continuation of systemic immunotherapy while maintaining ocular disease control.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving